Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Intravenous bisphosphonates

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
INTRODUCTION Intravenous bisphosphonates (IV BP) have been used to treat children with osteoporosis for many years. Favorable… Expand
2019
2019
Abstract Objectives: Skeletal-related events (SREs), i.e. pathologic fractures, spinal cord compression, surgery and radiation to… Expand
2019
2019
Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal‐related events for… Expand
2014
2014
OBJECTIVES To analyze whether oxidative stress (OS) changes are present in patients with bisphosphonate-related osteonecrosis of… Expand
2014
2014
AIM To determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ… Expand
  • table 1
  • table 2
  • table 3
  • table 5
2014
2014
PurposeThree bone-targeted agents (BTAs) are approved in the USA for prevention of bone complications among solid tumor patients… Expand
  • table 1
  • table 2
  • table 3
  • table 3
2013
2013
PurposeCancer patients with bone metastases (BMets) are predisposed to skeletal complications. Bone-targeted therapies such as… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Highly Cited
2012
Highly Cited
2012
PURPOSE Atypical femur fractures represent a potential complication of chronic oral bisphosphonate therapy in women with… Expand
2011
2011
PURPOSE The etiology of osteonecrosis of the jaw is poorly understood, but preferential mandibular uptake of intravenous… Expand
  • figure 1
  • table 1
Highly Cited
2007
Highly Cited
2007
PURPOSE Denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor-kappaB ligand, suppresses bone… Expand